JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(5):594-598, DEC 2007

DOI: 10.1097/QAI.0b013e318158c08e

,  

PMID: 18043313

Issn Print: 1525-4135

Publication Date: 2007/12/01


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

Chinese Pediatric Highly Active Antiretroviral Therapy Observational Cohort: A 1-Year Analysis of Clinical, Immunologic, and Virologic Outcomes

Fujie Zhang;Jessica Haberer;Yan Zhao;Zhihui Dou;Hongxin Zhao;Yun He;Guang Cao;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Background:Few data are available on the outcomes of pediatric antiretroviral therapy (ART) in the developing world.Methods:Eighty-three children were followed prospectively in China from July 2005 to August 2006 and received (zidovudine or stavudine) plus lamivudine plus (nevirapine or efavirenz).Results:Fifty-one children were ART naive at enrollment, and 32 were ART experienced. After 12 months, median weight increased by 0.3 weight for age z-score, median CD4 count increased from 116 to 340 cells/mm3 (P < 0.0001), and median viral load decreased from 5.53 to <2.60 log10 copies/mL (P < 0.0001) in the previously ART-naive children. In the ART-experienced children, median CD4 count increased from 193 to 318 cells/mm3 (P = 0.13), despite little change in median viral load (4.85 to 4.58 log10 copies/mL; P = 0.83). The viral load was <400 copies/mL in 55% of the previously ART-naive children and in 16% of the ART-experienced children.Conclusions:Weight and CD4 cell counts improved, and more than half of previously ART-naive patients had undetectable viral loads at 1 year. Future efforts should focus on improved virologic suppression through improved adherence and access to second-line regimens.

Related Topics

        loading  Loading Related Articles